PortfoliosLab logoPortfoliosLab logo
KNSA vs. UI
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

KNSA vs. UI - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Kiniksa Pharmaceuticals, Ltd. (KNSA) and Ubiquiti Inc. (UI). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, KNSA achieves a 80.22% return, which is significantly higher than UI's 0.81% return.


KNSA

1D
-4.94%
1M
18.22%
6M
69.26%
YTD
80.22%
1Y
145.67%
3Y*
57.85%
5Y*
37.13%
10Y*
ALL TIME*
14.55%

UI

1D
4.37%
1M
3.75%
6M
1.17%
YTD
0.81%
1Y
28.48%
3Y*
48.28%
5Y*
13.32%
10Y*
29.81%
ALL TIME*
27.64%
*Multi-year figures are annualized to reflect compound growth (CAGR)

Liquidity Comparison


PositionAvg. Volume Value (2W)Avg. Volume Value (1M)Avg. Volume Value (3M)
$68.75M$54.52M$46.86M
$45.54M$47.32M$74.80M

KNSA vs. UI - Yearly Performance Comparison


2026 (YTD)20252024202320222021202020192018
KNSA
Kiniksa Pharmaceuticals, Ltd.
80.22%108.54%12.77%17.09%27.27%-33.39%59.76%-60.63%14.89%
UI
Ubiquiti Inc.
0.81%67.72%141.15%-48.23%-9.99%10.83%48.49%91.65%24.28%

Correlation

The correlation between KNSA and UI is 0.08, meaning there was essentially no consistent relationship between their historical price movements. Each responded to its own set of market drivers.


Correlation
Correlation (1Y)
Focuses on recent behavior, but can change the most.

0.08

Correlation (3Y)
Balances recent behavior with more history.

0.20

Correlation (5Y)
Shows whether the relationship held over a longer period.

0.22

Correlation (All Time)
Calculated using the full available price history since May 24, 2018

0.21

The correlation between KNSA and UI shifts across timeframes, from 0.08 (1 year) to 0.22 (5 years), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap

KNSA:

$5.67B

UI:

$33.68B

EPS

KNSA:

$1.00

UI:

$15.56

PE Ratio

KNSA:

74.38

UI:

35.78

PEG Ratio

KNSA:

0.72

UI:

2.32

PS Ratio

KNSA:

7.14

UI:

10.89

PB Ratio

KNSA:

9.48

UI:

28.04

Total Revenue (TTM)

KNSA:

$840.85M

UI:

$3.10B

Gross Profit (TTM)

KNSA:

$546.22M

UI:

$1.42B

EBITDA (TTM)

KNSA:

$111.62M

UI:

$1.12B

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

KNSA vs. UI — Risk / Return Rank

Compare historical risk-adjusted metric ranks over the past 12 months.

KNSA
KNSA Risk / Return Rank: 9797
Overall Rank
KNSA Sharpe Ratio Rank: 9797
Sharpe Ratio Rank
KNSA Sortino Ratio Rank: 9797
Sortino Ratio Rank
KNSA Omega Ratio Rank: 9696
Omega Ratio Rank
KNSA Calmar Ratio Rank: 9797
Calmar Ratio Rank
KNSA Martin Ratio Rank: 9898
Martin Ratio Rank

UI
UI Risk / Return Rank: 6060
Overall Rank
UI Sharpe Ratio Rank: 6161
Sharpe Ratio Rank
UI Sortino Ratio Rank: 6161
Sortino Ratio Rank
UI Omega Ratio Rank: 6262
Omega Ratio Rank
UI Calmar Ratio Rank: 5858
Calmar Ratio Rank
UI Martin Ratio Rank: 5757
Martin Ratio Rank
The rank (0–100) uses a weighted average of the Sharpe, Sortino, Omega, Calmar, and Martin percentile ranks for the trailing 12 months. Higher means stronger historical risk-adjusted performance within the peer group.

KNSA vs. UI - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Kiniksa Pharmaceuticals, Ltd. (KNSA) and Ubiquiti Inc. (UI). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


KNSAUIDifference
Sharpe ratioReturn per unit of total volatility

+2.48

Sortino ratioReturn per unit of downside risk

+3.09

Omega ratioGain probability vs. loss probability

1.52

1.15

+0.37

Calmar ratioReturn relative to maximum drawdown

6.94

0.55

+6.39

Martin ratioReturn relative to average drawdown

24.13

1.06

+23.07

KNSA vs. UI - Sharpe Ratio Comparison

The current KNSA Sharpe Ratio is 2.94, which is higher than the UI Sharpe Ratio of 0.46. The chart below compares the historical Sharpe Ratios of KNSA and UI, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

KNSA vs. UI - Drawdown Comparison

The maximum KNSA drawdown since its inception was -83.06%, which is greater than UI's maximum drawdown of -77.49%. Use the drawdown chart below to compare losses from any high point for KNSA and UI.


Loading charts...

Drawdown Indicators


KNSAUIDifference

Max Drawdown

Largest peak-to-trough decline

-83.06%

-77.49%

-5.57%

Max Drawdown (1Y)

Largest decline over 1 year

-21.12%

-51.73%

+30.61%

Max Drawdown (3Y)

Largest decline over 3 years

-34.14%

-51.73%

+17.59%

Max Drawdown (5Y)

Largest decline over 5 years

-53.17%

-69.44%

+16.27%

Max Drawdown (10Y)

Largest decline over 10 years

-72.21%

Current Drawdown

Current decline from peak

-8.13%

-48.62%

+40.49%

Average Drawdown

Average peak-to-trough decline

-40.09%

-26.76%

-13.33%

Ulcer Index

Depth and duration of drawdowns from previous peaks

6.06%

27.01%

-20.95%

Volatility

KNSA vs. UI - Volatility Comparison

Kiniksa Pharmaceuticals, Ltd. (KNSA) has a higher volatility of 26.47% compared to Ubiquiti Inc. (UI) at 9.02%. This indicates that KNSA's price experiences larger fluctuations and is considered to be riskier than UI based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


KNSAUIDifference

Volatility (1M)

Calculated over the trailing 1-month period

26.47%

9.02%

+17.45%

Volatility (6M)

Calculated over the trailing 6-month period

41.55%

40.43%

+1.12%

Volatility (1Y)

Calculated over the trailing 1-year period

49.77%

61.85%

-12.08%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

54.77%

48.76%

+6.01%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

64.34%

48.02%

+16.32%

Dividends

KNSA vs. UI - Dividend Comparison

KNSA has not paid dividends to shareholders, while UI's dividend yield for the trailing twelve months is around 0.58%.


PositionTTM20252024202320222021202020192018
KNSA
Kiniksa Pharmaceuticals, Ltd.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
UI
Ubiquiti Inc.
0.58%0.51%0.72%1.72%0.88%0.65%0.50%0.58%0.50%

Financials

KNSA vs. UI - Financials Comparison

This section allows you to compare key financial metrics between Kiniksa Pharmaceuticals, Ltd. and Ubiquiti Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items

KNSA vs. UI - Profitability Comparison

The chart below illustrates the profitability comparison between Kiniksa Pharmaceuticals, Ltd. and Ubiquiti Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

KNSA - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Aug 2026, Kiniksa Pharmaceuticals, Ltd. reported a gross profit of 220.03M and revenue of 243.60M. Therefore, the gross margin over that period was 90.3%.

UI - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Aug 2026, Ubiquiti Inc. reported a gross profit of 370.71M and revenue of 788.20M. Therefore, the gross margin over that period was 47.0%.

KNSA - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Aug 2026, Kiniksa Pharmaceuticals, Ltd. reported an operating income of 27.19M and revenue of 243.60M, resulting in an operating margin of 11.2%.

UI - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Aug 2026, Ubiquiti Inc. reported an operating income of 290.82M and revenue of 788.20M, resulting in an operating margin of 36.9%.

KNSA - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Aug 2026, Kiniksa Pharmaceuticals, Ltd. reported a net income of 25.43M and revenue of 243.60M, resulting in a net margin of 10.4%.

UI - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Aug 2026, Ubiquiti Inc. reported a net income of 233.91M and revenue of 788.20M, resulting in a net margin of 29.7%.


Frequently Asked Questions


KNSA and UI have a correlation of 0.08, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

KNSA has higher volatility (26.47%) compared to UI (9.02%). In terms of maximum drawdown, KNSA dropped -83.06% vs UI's -77.49%.

KNSA currently has the higher Sharpe Ratio (2.94 vs 0.46), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for KNSA and UI

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer